Video: Tasigna(R) Demonstrates Rapid Response as Initial Therapy in Life-Threatening Form o...(ogy.us/ target _new www.novartisoncolog...),Health

References

    (1) Cortes J, et al. Efficacy of Nilotinib (AMN107) in Patients (Pts)
     with Newly Diagnosed, Previously Untreated Philadelphia Chromosome
    (Ph)-Positive Chronic Myelogenous Leukemia in Early Chronic Phase
    (CML-CP). Abstract # 446. American Society of Hematology 2008 Annual
    Meeting, San Francisco, CA.

    (2) Rosti G, et al. High and Early Rates of Cytogenetic and Molecular
    Response with Nilotinib 800 Mg Daily as First Line Treatment of
    Ph-Positive Chronic Myeloid Leukemia in Chronic Phase: Results of a Phase
    2 Trial of the GIMEMA CML Working Party. Abstract # 181. American Society
    of Hematology 2008 Annual Meeting, San Francisco, CA.

    (3) Gleevec(R) (imatinib mesylate) tablets prescribing information. East
    Hanover, NJ: Novartis Pharmaceuticals Corporation; Nov 2007.

    *Known as Glivec(R) (imatinib) outside the US, Canada and Israel.

Media Contacts:

    Media only:
    Kim Fox
    Novartis Oncology
    P: +1 862 778 7692
    Dana Kahn Cooper
    P: +1 732 817 1800
    C: +1 732 239 6664

    Investors only:
    Richard Jarvis
    Novartis Corporation
    P: +1 212 830 2433